Related Experiment Video
Updated: Feb 23, 2026
06:11
A Conflict Model of Reward-seeking Behavior in Male Rats
Published on: February 20, 2019
7.9K
Dopamine Agonists and Impulse Control Disorders: A Complex Association.
Marie Grall-Bronnec1,2, Caroline Victorri-Vigneau3,4, Yann Donnio5
1Clinical Investigation Unit "Behavioral Addictions/Complex Affective Disorders", Addictology and Psychiatry Department, CHU Nantes, Hospital Saint Jacques, 85, rue Saint Jacques, 44093, Nantes Cedex 1, France. marie.bronnec@chu-nantes.fr.
Drug Safety
|September 2, 2017
Summary
Dopamine agonist (DAA) use is linked to impulse control disorders (ICDs), particularly in Parkinson's disease patients. Factors like DAA type, dosage, and patient characteristics influence ICD development.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Impulse control disorders (ICDs) are recognized adverse effects of dopamine agonist (DAA) therapy.
- DAAs are commonly prescribed for Parkinson's disease (PD), restless legs syndrome (RLS), and prolactinoma.
Purpose of the Study:
- To critically review the prevalence and associated factors of ICD development during DAA use.
- To synthesize current data on the relationship between DAAs and ICDs.
Main Methods:
- A systematic literature search was conducted on two electronic databases from inception to July 2017.
- Included articles focused on ICDs, dopaminergic drugs, and were original research.
Main Results:
- Ninety articles were included from 584 potential studies.
- ICD prevalence varied widely (2.6–34.8%) in Parkinson's disease patients, with lower rates in RLS patients. Limited data existed for prolactinoma.
- Key factors associated with ICD development included DAA type, dosage, male gender, younger age, psychiatric history, earlier disease onset, longer disease duration, and PD motor complications.
Conclusions:
- DAA use increases the risk of ICDs, influenced by a combination of drug-specific and patient-related factors.
- Existing guidelines for ICD prevention and treatment are available, but further research is needed to identify at-risk individuals.
Related Concept Videos
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.5K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.5K
01:15Drug Abuse and Addiction: Pharmacological Phenomena
1.3K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.3K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:25Adrenergic Agonists: Indirect-Acting Agents
2.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.9K
01:30Attention-Deficit/Hyperactivity Disorder
1.1K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.1K
01:29Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K